Work

Wcn26-4078 Effect of Once-weekly Semaglutide 1.0 Mg on Kidney Outcomes by Baseline Characteristics: Exploratory Data From the Flow Trial

Year: 2026

Type: article

Abstract: Background and aims: In the FLOW trial (NCT03819153), semaglutide reduced the risk of major kidney and cardiovascular (CV) events and all-cause death. This analysis explored the effect of semaglutide on key kidney outcomes by baseline characteristics.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2026.104616

Authors: Srikanth Bellary, Richard E. Pratley, Katherine R. Tuttle, Peter Rossing, Kenneth W. Mahaffey, Prachi Priyadarshini, Christine Sofie Fuchs Jacobsen, Poornima KN, Johannes F.E. Mann

Institutions: Aston University, AdventHealth Orlando, AdventHealth, University of Washington, Steno Diabetes Center Copenhagen, Stanford Medicine, Stanford University, Novo Nordisk (India), Novo Nordisk (Denmark)

Language: English

Topic: Chronic Kidney Disease and Diabetes

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,800

OpenAlex ID: W7140300199

FWCI:

Cites:

Cited by:

Related to: 10